Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical ASCVD Study

Documenti analoghi

• Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )
  di: Lauren Wilson, et al.
  Pubblicazione: (2026)
• Preventing Atherosclerotic Cardiovascular Disease in Young Male Androgen Abusers
  di: Peter Bond, et al.
  Pubblicazione: (2026)
• Targeting Different Lesion Locations in Lower Extremity Atherosclerotic Disease: Insights From Cardiovascular Risk Factor Profiling
  di: Wenzhuo Meng, et al.
  Pubblicazione: (2026)
• Missed Opportunities to Intensify Lipid‐Lowering Therapy in Patients With Atherosclerotic Cardiovascular Disease: A Retrospective Cohort Study
  di: Hannah Ayers, et al.
  Pubblicazione: (2026)
• One in Five Atherosclerotic Cardiovascular Disease Events in Individuals With Diabetes Attributed to Elevated Remnant Cholesterol
  di: Benjamin N. Wadström, et al.
  Pubblicazione: (2024)